This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Kingsway Joins Club of Insurance Losers

NEW YORK ( TheStreet) -- Embroiled in a dispute with Pennsylvania's insurance regulator, Kingsway Financial Services (KFS - Get Report) is in trouble.

The Ontario-based insurer gifted ownership of a U.S. subsidiary to 20 charities to limit its liabilities, and now the company looks terminal. Its stock price stands at a little more than $1.

It's not the only insurer whose shares have swung wildly as the credit crisis, worsened by the recession, has meant investing has become a buy-or-sell opportunity depending on the news of the day. Some companies' stocks, such as Ambac (ABK) or Radian (RDN - Get Report), are driven by rumor as much as profits or losses, or other facts.

Kingsway's stock has dropped more than 67% in a month, dragged down by the dispute with the insurance regulator. Ambac has fallen 29%, hurt by late filings, revelations of misstatements and the resignation of its chief financial officer. Insurance shares also rise on the barest of good news these days. Radian's stock popped 23% on Tuesday on lower-than-expected delinquency rates.

Kingsway is unlike Ambac in one way: Its beta (or stock-market correlation) of 0.84 is the opposite of Ambac's 2.15. You expect high returns for risking your money with Ambac. What you don't expect is the high risk that comes with Kingsway's low beta.

Kingsway's 74% decline in the past year is the worst performance of any insurance stock, with Ambac at No. 2. If it prevails in its court case with Pennsylvania's insurance regulator, Kingsway will get a reprieve, and its stock will certainly rocket. As with Ambac, whose stock is well below $1, Kingsway is massively speculative.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BAC $16.53 -0.12%
KFS $5.98 0.00%
JPM $66.08 0.00%
MBI $8.81 0.00%
RDN $17.88 0.00%

Markets

DOW 18,040.37 +29.69 0.16%
S&P 500 2,111.73 +4.34 0.21%
NASDAQ 5,082.9290 +12.9030 0.25%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs